1665 related articles for article (PubMed ID: 34723159)
1. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera.
Tada T; Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR
iScience; 2021 Nov; 24(11):103341. PubMed ID: 34723159
[TBL] [Abstract][Full Text] [Related]
2. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
bioRxiv; 2021 Nov; ():. PubMed ID: 34790980
[TBL] [Abstract][Full Text] [Related]
3. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
[TBL] [Abstract][Full Text] [Related]
4. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
5. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
[TBL] [Abstract][Full Text] [Related]
6. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.
Tada T; Dcosta BM; Samanovic-Golden M; Herati RS; Cornelius A; Mulligan MJ; Landau NR
bioRxiv; 2021 Feb; ():. PubMed ID: 33564768
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q.
Wilhelm A; Toptan T; Pallas C; Wolf T; Goetsch U; Gottschalk R; Vehreschild MJGT; Ciesek S; Widera M
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578275
[TBL] [Abstract][Full Text] [Related]
9. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies.
Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
bioRxiv; 2021 Mar; ():. PubMed ID: 33791698
[TBL] [Abstract][Full Text] [Related]
10. The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera.
Li G; Zhou Z; Du P; Yu M; Li N; Xiong X; Huang H; Liu Z; Dai Q; Zhu J; Guo C; Wu S; Baptista-Hon DT; Miao M; Ming LW; Wu Y; Zeng F; Zhang CL; Zhang ED; Song H; Liu J; Lau JY; Xiang AP; Zhang K
Precis Clin Med; 2021 Sep; 4(3):149-154. PubMed ID: 35693215
[TBL] [Abstract][Full Text] [Related]
11. Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity.
Zhang L; Li Q; Wu J; Yu Y; Zhang Y; Nie J; Liang Z; Cui Z; Liu S; Wang H; Ding R; Jiang F; Li T; Nie L; Lu Q; Li J; Qin L; Jiang Y; Shi Y; Xu W; Huang W; Wang Y
Emerg Microbes Infect; 2022 Dec; 11(1):1024-1036. PubMed ID: 35293847
[TBL] [Abstract][Full Text] [Related]
12. Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda.
Liu S; Huynh T; Stauft CB; Wang TT; Luan B
J Chem Inf Model; 2021 Oct; 61(10):5133-5140. PubMed ID: 34648284
[TBL] [Abstract][Full Text] [Related]
13. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.
Cherian S; Potdar V; Jadhav S; Yadav P; Gupta N; Das M; Rakshit P; Singh S; Abraham P; Panda S; Team N
Microorganisms; 2021 Jul; 9(7):. PubMed ID: 34361977
[TBL] [Abstract][Full Text] [Related]
15. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
Wu K; Werner AP; Moliva JI; Koch M; Choi A; Stewart-Jones GBE; Bennett H; Boyoglu-Barnum S; Shi W; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
bioRxiv; 2021 Jan; ():. PubMed ID: 33501442
[TBL] [Abstract][Full Text] [Related]
16. The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines.
Yang X; Zhu Y; Xun J; Liu J; Wen Q; Lin Y; Shen X; Chen J; Yuan S; Zhao X; Wang J; Pan H; Yang J; Liang Z; Liang Y; Lin Q; Liang H; Zhou C; Jin L; Xie W; Liu J; Lu D; Ying T; Shen Y; Zhang X; Xu J; Yin C; Wang P; Jiang S; Lu H; Zhu H
iScience; 2022 Sep; 25(9):105016. PubMed ID: 36062074
[TBL] [Abstract][Full Text] [Related]
17. A rapid screening assay for L452R and T478K spike mutations in SARS-CoV-2 Delta variant using high-resolution melting analysis.
Aoki A; Adachi H; Mori Y; Ito M; Sato K; Okuda K; Sakakibara T; Okamoto Y; Jinno H
J Toxicol Sci; 2021; 46(10):471-476. PubMed ID: 34602531
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera.
Yahalom-Ronen Y; Erez N; Fisher M; Tamir H; Politi B; Achdout H; Melamed S; Glinert I; Weiss S; Cohen-Gihon I; Israeli O; Izak M; Mandelboim M; Caraco Y; Madar-Balakirski N; Mechaly A; Shinar E; Zichel R; Cohen D; Beth-Din A; Zvi A; Marcus H; Israely T; Paran N
Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214749
[TBL] [Abstract][Full Text] [Related]
19. Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD-A Target for Vaccine Development.
Gupta D; Kumar M; Sharma P; Mohan T; Prakash A; Kumari R; Kaur P
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679867
[TBL] [Abstract][Full Text] [Related]
20. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.
Edara VV; Lai L; Sahoo MK; Floyd K; Sibai M; Solis D; Flowers MW; Hussaini L; Ciric CR; Bechnack S; Stephens K; Mokhtari EB; Mudvari P; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Graham BS; Wrammert J; Douek DC; Boritz E; Pinsky BA; Suthar MS
bioRxiv; 2021 May; ():. PubMed ID: 34013272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
